These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11961194)

  • 1. Viral oncolysis.
    Mullen JT; Tanabe KK
    Oncologist; 2002; 7(2):106-19. PubMed ID: 11961194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral oncolysis for malignant liver tumors.
    Mullen JT; Tanabe KK
    Ann Surg Oncol; 2003 Jul; 10(6):596-605. PubMed ID: 12839843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.
    Shah AC; Benos D; Gillespie GY; Markert JM
    J Neurooncol; 2003 Dec; 65(3):203-26. PubMed ID: 14682372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral oncolysis.
    Donahue JM; Mullen JT; Tanabe KK
    Surg Oncol Clin N Am; 2002 Jul; 11(3):661-80. PubMed ID: 12487061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
    Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
    Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
    Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
    Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
    Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
    FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytolytic viruses as potential anti-cancer agents.
    Ring CJA
    J Gen Virol; 2002 Mar; 83(Pt 3):491-502. PubMed ID: 11842243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction.
    Campbell SA; Gromeier M
    Onkologie; 2005 Mar; 28(3):144-9. PubMed ID: 15772465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic viruses as novel anticancer agents: turning one scourge against another.
    Smith ER; Chiocca EA
    Expert Opin Investig Drugs; 2000 Feb; 9(2):311-27. PubMed ID: 11060679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.
    Wildner O
    Curr Opin Mol Ther; 2003 Aug; 5(4):351-61. PubMed ID: 14513677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer.
    Jefferson A; Cadet VE; Hielscher A
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):407-16. PubMed ID: 25900073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
    Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
    Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccinia as a vector for gene delivery.
    Guo ZS; Bartlett DL
    Expert Opin Biol Ther; 2004 Jun; 4(6):901-17. PubMed ID: 15174972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions: oncolytic viruses.
    You L; He B; Xu Z; McCormick F; Jablons DM
    Clin Lung Cancer; 2004 Jan; 5(4):226-30. PubMed ID: 14967074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.